The medical cannabis company Odi Pharma reports a sharply increased revenue and a positive result for the third quarter in the broken fiscal year.Revenue rose to SEK 12.7 million from SEK 2.9 million in the corresponding quarter of the previous year.In the report, Chairman Volker Wiederrich states that the company achieved record sales over the past three quarters and that sales so far in the fiscal year already exceed the previous full-year record. Operating profit improved to SEK 0.3 million from SEK -0.2 million, while profit before tax amounted to SEK 0.1 million compared with SEK -0.3 million the year before. Earnings per share amounted to 0.01 (-0.02)."Going forward, our strategy remains unchanged. Odi will continue to work with both strategic and organic expansion within the regulated European markets for medical cannabis. We continue to focus on disciplined execution, sustainable growth and long-term value creation. With a stronger financial position, growing market shares and improved business visibility, the company's outlook looks bright," says Wiederreich.Odi Pharma, SEK millionOutcome Q3 2025/26Q3 2024/25Change (%)Revenue12.72.9333.2%Operating profit0.3-0.2Profit before tax0.1-0.3Earnings per share0.01-0.02